For 2026, Alkermes guided total revenues of $1.73 billion to $1.84 billion, including proprietary product net sales of $1.52 billion to $1.60 billion. It expects manufacturing and royalty revenues of $210 million to $240 million, reflecting scheduled expiration of certain XEPLION royalties that phase out on a country-by-country basis in the second half of 2026. The company also noted that its VUMERITY manufacturing obligations were completed in 2025, with future VUMERITY revenue expected to be solely royalt ...

Summary of Savara's Conference Call Company Overview - **Company**: Savara - **Focus**: Clinical stage biopharmaceutical company specializing in rare respiratory diseases - **Product**: Developing MOLBREEVI, an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) for autoimmune pulmonary alveolar proteinosis (APAP) [1][3] Recent Progress - **FDA Submission**: BLA (Biologics License Application) accepted by the FDA with a priority review assigned, PDUFA date set for August 22nd [3][4] - **Clinical Trials**: Positive results from the global phase III study (IMPALA-2) for APAP, supporting confidence in the approval process [3][6] Unmet Need and Treatment Landscape - **Current Situation**: No approved therapies for APAP in the U.S. and Europe; existing treatment involves a mechanical procedure (whole lung lavage) that is not standardized and only available in select centers [8][10] - **MOLBREEVI's Advantage**: Addresses the underlying pathophysiology of APAP by activating macrophages, improving gas exchange and surfactant homeostasis [11] Market Potential - **Patient Population**: Estimated 5,500 diagnosed patients in the U.S., equating to approximately 16 patients per million, which is within the published range of 6-26 patients per million for this rare disease [14][15] - **Treatment Accessibility**: All identified patients could potentially benefit from MOLBREEVI upon approval, with physicians indicating willingness to prescribe it regardless of disease severity [15][19] Commercial Strategy - **Field Force**: Plans to establish a commercial field force of approximately 30 customer-facing personnel, focusing on the top 500 accounts that manage two-thirds of the patient population [20][21] - **Partnerships**: Selected PANTHERx Rare as the exclusive specialty pharmacy, leveraging their experience in rare diseases and existing relationships with pulmonary offices [22][23] Financial Position - **Cash Reserves**: As of the last report, Savara has $264 million in cash, with potential access to an additional $150 million in non-dilutive financing upon FDA approval [26][27] - **Funding Strategy**: Includes a royalty agreement and a debt facility to support operations and commercialization efforts [27] Additional Insights - **Launch Preparations**: Ongoing disease awareness campaigns and educational initiatives are being conducted to prepare for the commercialization of MOLBREEVI [24][25] - **Long-term Outlook**: The company is well-funded and positioned for a successful launch, with a strong focus on addressing the needs of APAP patients [27][28]

Key Takeaways Repligen posted Q4 2025 EPS of 49 cents, beating estimates. Revenues rose 18% Y/Y to $198M.Repligen delivered 14% organic growth in Q4 2025, with Proteins and Process Analytics up over 30%.Repligen guides 2026 revenues of $810-$840M and estimates EPS to be in the band of $1.93-$2.01.Repligen Corporation (RGEN) reported fourth-quarter 2025 adjusted earnings per share of 49 cents, which came ahead of the Zacks Consensus Estimate and the year-ago adjusted earnings of 44 cents per share.Total reve ...

Live Chat on The Biotech Forum sees frequent discussion of specific covered call trades. To see what covered call trades I am currently executing along with a model portfolio of attractive biotech stocks, just initiate your free trial into The Biotech Forum by clicking HERE .Shares of skin disease concern Oruka Therapeutics, Inc. ( ORKA ) have more than doubled since its IL-23p19 antagonist ORKA-001 demonstrated a half-life four times greater than Skyrizi in a Phase 1 study. The once or twice-yearlyBret Jen ...

United Therapeutics (NasdaqGS:UTHR) Q4 2025 Earnings call February 25, 2026 09:00 AM ET Company ParticipantsAshish Varma - Group Internal Audit - AI Initiatives ManagerDewey Steadman - Head of Investor RelationsLeigh Peterson - EVP of Product Development and XenotransplantationMartine Rothblatt - Chairperson and CEOMichael Benkowitz - President and COOConference Call ParticipantsJoseph Thome - Managing Director and Senior Research AnalystRoanna Ruiz - Senior Research AnalystRoger Song - Senior Equity Resear ...

United Therapeutics (NasdaqGS:UTHR) Q4 2025 Earnings call February 25, 2026 09:00 AM ET Company ParticipantsAshish Varma - Group Internal Audit - AI Initiatives ManagerDewey Steadman - Head of Investor RelationsLeigh Peterson - EVP of Product Development and XenotransplantationMartine Rothblatt - Chairperson and CEOMichael Benkowitz - President and COOConference Call ParticipantsJoseph Thome - Managing Director and Senior Research AnalystRoanna Ruiz - Senior Research AnalystRoger Song - Senior Equity Resear ...

United Therapeutics (NasdaqGS:UTHR) Q4 2025 Earnings call February 25, 2026 09:00 AM ET Speaker5Please also know today's event is being recorded. At this time, I'd like to turn the webcast over to Dewey Steadman, Investor Relations Manager at United Therapeutics.Speaker1Thank you, Jamie. Good morning. It is my pleasure to welcome you to the United Therapeutics Corporation 4th quarter 2025 corporate update webcast. Remarks today will include forward-looking statements representing our expectations or beliefs ...

InflaRx (NasdaqGS:IFRX) FY Conference February 25, 2026 08:40 AM ET Company ParticipantsNiels C. Riedemann - CEO and FounderConference Call ParticipantsAndreas Argyrides - Executive Director and Senior AnalystAndreas ArgyridesAll right. Hey, good morning, everyone. Welcome to Oppenheimer's 36th Annual Healthcare Life Sciences Conference. My name is Andreas Argyrides. I'm one of the senior biotech analysts at Oppenheimer, and today I have the pleasure to be joined by Niels C. Riedemann, CEO, and Jan Medina, ...

Ionis Pharmaceuticals (NasdaqGS:IONS) Q4 2025 Earnings call February 25, 2026 08:30 AM ET Company ParticipantsBeth Hougen - Executive VP and CFOBrett Monia - CEO, Member of the Board of Directors and Founding ScientistEric Swayze - Executive Vice President of ResearchEugene Schneider - Executive VP, Chief Clinical Development and Operations OfficerHolly Kordasiewicz - Executive VP and Chief Development OfficerKyle Jenne - Executive VP and Chief Global Product Strategy OfficerMichael Ulz - Executive Director ...

5 Very Safe High-Yield Dividend Stocks Boomers Can Hold Forever - 24/7 Wall St.[S&P 5006,919.80 +0.42%] [Dow Jones49,382.90 +0.44%][Nasdaq 10025,095.40 +0.46%][Russell 20002,672.51 +0.79%][FTSE 10010,783.00 +0.64%][Nikkei 22559,570.30 +2.83%][Stock Market Live February 25, 2026: S&P 500 (SPY) Up on Trump and Tech][Investing]# 5 Very Safe High-Yield Dividend Stocks Boomers Can Hold Forever### Quick ReadThe Social Security cost-of-living adjustment (COLA) for 2026 was just 2.8%.The COLA for this year worked o ...